Programmed cell death 1 inhibitor sintilimab plus S-1 and gemcitabine for liver metastatic pancreatic ductal adenocarcinoma
The combination of PD-1 inhibitor sintilimab with S-1 and gemcitabine demonstrated effectiveness and safety for treating liver metastatic PDAC, meriting further investigation.
Authors
- S. Zhang
- Qinghua Ke (ORCID: https://orcid.org/0009-0009-3146-2519)
- Shi-Qiong Zhou
- Yuan Ren (ORCID: https://orcid.org/0009-0009-3503-0780)
- Hongtao Li (ORCID: https://orcid.org/0000-0001-6532-2092)
- Peng Wan (ORCID: https://orcid.org/0000-0002-0133-3099)
Institutions
- Yangtze University (CN)
- First People's Hospital of Jingzhou (CN)
Publication Details
- Journal
- World Journal of Clinical Oncology
- Published
- 2024-12-11
- DOI
- https://doi.org/10.5306/wjco.v16.i2.98079
- Primary Topic
- Pancreatic and Hepatic Oncology Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00